| 24 | 0 | 56 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 建立注射用福沙匹坦双葡甲胺的药物利用评价(DUE)标准，并采用加权优劣解距离(TOPSIS)法评价该药物的使用合理性。方法 以药品说明书为基础，参考相关指南、专家共识及循证医学证据，制定注射用福沙匹坦双葡甲胺DUE标准。随机抽取2023年6月至2024年6月使用注射用福沙匹坦双葡甲胺的病历300份，采用加权TOPSIS法对该药物的合理性进行评价。结果 在注射用福沙匹坦双葡甲胺DUE标准中，11个二级指标按相对权重系数进行排名，前3位依次是适应证、给药剂量和给药疗程。300份病历中用药方案与最优方案接近程度(Ci)≥0.8(合理)的病历有134份(占44.67%);0.6≤Ci<0.8(基本合理)的病历有15份(占5.00%),Ci<0.6(不合理)的病历有151份(占50.33%)。不合理用药主要表现为不符合适应证用药、用药疗程过长、给药时机不适宜和联合用药不规范等方面。结论 基于加权TOPSIS法的注射用福沙匹坦双葡甲胺DUE方法可综合多个评价指标，客观全面地反映药物利用情况。我院注射用福沙匹坦双葡甲胺的临床应用中存在较多不合理现象，应针对性地进行管理以促进合理用药。
Abstract：AIM To establish the drug use evaluation(DUE) criteria for fosaprepitant dimeglumine for injection, and evaluate its clinical utilization using the weighted technique for order preference by similarity to ideal solution(TOPSIS) method. METHODS DUE criteria were developed based on the package insert and evidence-based medical evidence. The weighted TOPSIS method was applied to assess the rationality of 300 randomly selected medical records involving fosaprepitant dimeglumine for injection at our hospital from June 2023 to June 2024. RESULTS The top 3 weights in the 11 secondary indicators of DUE criteria for fosaprepitant dimeglumine for injection were indications, dosage, and duration of treatment. Among the 300 cases, 134(44.67%) showed a closeness index(Ci) ≥ 0.8(rational), 15(5.00%) had 0.6 ≤ Ci <0.8(marginally rational), and 151(50.33%) exhibited Ci < 0.6(irrational). The main issues of irrational use included offlabel indications, prolonged treatment duration, inappropriate timing of administration, and nonstandard combination therapies. CONCLUSION The weighted TOPSIS-based DUE method comprehensively evaluates multiple indicators and objectively reflects the utilization of fosaprepitant dimeglumine for injection. Significant irrational use is identified in our hospital, highlighting the necessity for enhanced management to ensure appropriate medication use.
[1]中国药学会医院药学专业委员会,张玉.化疗所致恶心呕吐的药物防治指南[J].中国医院药学杂志,2022,42(5):457.
[2]何光照,王为欢,贺国芳.止吐新药:神经激肽1受体拮抗药福沙匹坦[J].中国药师,2016,19(4):752.
[3]RAZVI Y,CHAN S,MCFARLANE T,et al.ASCO,NCCN,MASCC/ESMO:a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients[J].Support Care Cancer,2019,27(1):87.
[4]中国抗癌协会肿瘤临床化疗专业委员会,中国抗癌协会肿瘤支持治疗专业委员会.中国肿瘤药物治疗相关恶心呕吐防治专家共识(2022年版)[J].中华医学杂志,2022,102(39):3080.
[5]中国抗癌协会肿瘤支持治疗专业委员会,袁响林.延迟性恶心呕吐防治中国专家共识(2022年版)[J].临床肿瘤学杂志,2023,28(5):442.
[6]上海市抗癌协会癌症康复与姑息治疗专业委员会,上海市抗癌协会肿瘤药物临床研究专业委员会,中国老年保健协会肿瘤防治与临床研究管理专业委员会.抗肿瘤治疗所致恶心呕吐全程管理上海专家共识(2024年版)[J].中国癌症杂志,2024,34(1):104.
[7]王彪,潘祺琦.2018—2021年南京地区预防化疗所致恶心呕吐药物应用现状调查与分析[J].中国新药杂志,2023,32(11):1171.
[8]PIECHOTTA V,ADAMS A,HAQUE M,et al.Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy:a network meta-analysis[J].Cochrane Database Syst Rev,2022,11(11):CD012775.
[9]EDWARDS J K,BOSSAER J B,LEWIS P O,et al.Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant[J].J OncolPharm Pract,2020,26(4):809.
[10]AFANASJEVA J,BURK M,CUNNINGHAM F F,et al.ASHP guidelines on medication-use evaluation[J].Am J Health Syst Pharm,2021,78(2):168.
[11]钱自明,王猛.基于属性层次模型赋权法和加权TOPSIS法评价急诊儿科头孢地尼的用药合理性[J].中国临床药学杂志,2024,33(4):259.
[12]杨蕊,白婷,朱琳,等.基于AHM赋权法和TOPSIS法的转化糖电解质注射液合理性评价[J].中国临床药学杂志,2022,31(10):731.
[13]WEIBEL S,RÜCKER G,EBERHART L H,et al.Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia:a network meta-analysis[J].Cochrane Database Syst Rev,2020,10(10):CD012859.
[14]VAN LAERE K,DE HOON J,BORMANS G,et al.Equivalent dynamic human brain NK1-receptor occupancy following singledose i.v.fosaprepitant vs.oral aprepitant as assessed by PET imaging[J].Clin Pharmacol Ther,2012,92(2):243.
[15]ANDO Y,HAYASHI T,ITO K,et al.Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy[J].Support Care Cancer,2016,24(2):871.
[16]WEINSTEIN C,JORDAN K,GREEN S A,et al.Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy:results of a randomized,double-blind phaseⅢtrial[J].Ann Oncol,2016,27(1):172.
[17]CHAU E,LUNDBERG J,PHILLIPS G,et al.Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant[J].J Oncol Pharm Pract,2019,25(5):1053.
基本信息:
DOI：10.19577/j.1007-4406.2026.08.009
中图分类号:R969.3
引用信息:
[1]上官琰,冯嘉丽,朱倩,等.基于加权TOPSIS法的注射用福沙匹坦双葡甲胺药物利用评价[J].中国临床药学杂志,2026,35(08):723-728.DOI:10.19577/j.1007-4406.2026.08.009.
2026-08-25
2026-08-25